DNA methyltransferase inhibitors: class effect or unique agents?
Griffiths
Elizabeth A
EA
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Gore
Steven D
SD
D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors*; D000077209:Decitabine; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D016896:Treatment Outcome
D000077209:Decitabine; D015254:DNA Modification Methylases; D001374:Azacitidine